Biofrontera Inc (BFRI)

$0.92 +0.03 (2.86%)
Market Cap 6.93M
Revenue (ttm) 34.07M
Net Income (ttm) -20.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -59.08%
Debt to Equity Ratio 0.00
Volume 42,500
Avg Vol 459,524
Day's Range N/A - N/A
Shares Out 7.75M
Stochastic %K 35%
Beta 0.30
Analysts Strong Sell
Price Target $11.50

Latest News on BFRI

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Jan 8, 2025, 9:50 AM EST - 2 months ago

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Dec 23, 2024, 9:30 AM EST - 2 months ago

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Dec 3, 2024, 11:00 AM EST - 3 months ago

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Nov 22, 2024, 9:10 AM EST - 3 months ago

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 3:02 PM EST - 4 months ago

Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Nov 13, 2024, 5:15 PM EST - 4 months ago

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Nov 1, 2024, 11:55 AM EDT - 4 months ago

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 31, 2024, 10:32 AM EDT - 4 months ago

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 14, 2024, 10:30 AM EDT - 5 months ago

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Oct 7, 2024, 8:45 AM EDT - 5 months ago

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 25, 2024, 10:45 AM EDT - 5 months ago

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 1:34 PM EDT - 7 months ago

Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 14, 2024, 4:30 PM EDT - 7 months ago

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Aug 9, 2024, 10:00 AM EDT - 7 months ago

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Jun 24, 2024, 8:30 AM EDT - 9 months ago

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript

May 16, 2024, 2:44 PM EDT - 10 months ago

Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

May 15, 2024, 4:45 PM EDT - 10 months ago

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

May 6, 2024, 10:30 AM EDT - 10 months ago

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

May 3, 2024, 8:50 AM EDT - 11 months ago

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

Mar 26, 2024, 4:30 PM EDT - 1 year ago

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 12:13 PM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Mar 15, 2024, 8:25 PM EDT - 1 year ago

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Mar 15, 2024, 6:10 PM EDT - 1 year ago

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024

Mar 8, 2024, 9:00 AM EST - 1 year ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024

Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer

Mar 5, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer

Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

Feb 23, 2024, 8:40 AM EST - 1 year ago

Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

Feb 20, 2024, 8:10 AM EST - 1 year ago

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules

Feb 20, 2024, 8:05 AM EST - 1 year ago

Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

Feb 5, 2024, 5:15 PM EST - 1 year ago

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023

Jan 11, 2024, 4:15 PM EST - 1 year ago

Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023

Biofrontera Inc. (BFRI) Q3 2023 Earnings Call Transcript

Nov 10, 2023, 1:54 PM EST - 1 year ago

Biofrontera Inc. (BFRI) Q3 2023 Earnings Call Transcript

Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update

Nov 9, 2023, 5:10 PM EST - 1 year ago

Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10

Nov 3, 2023, 8:30 AM EDT - 1 year ago

Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10

Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules

Oct 31, 2023, 8:01 AM EDT - 1 year ago

Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

Oct 10, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference

Oct 5, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference

Biofrontera Inc. Announces Preliminary Third Quarter Revenues

Oct 4, 2023, 8:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Preliminary Third Quarter Revenues

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

Aug 29, 2023, 8:00 AM EDT - 1 year ago

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

Aug 28, 2023, 8:00 AM EDT - 1 year ago

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

Biofrontera Inc. (BFRI) Q2 2023 Earnings Call Transcript

Aug 11, 2023, 10:12 AM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q2 2023 Earnings Call Transcript

Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 11, 2023, 7:00 AM EDT - 1 year ago

Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma

Aug 10, 2023, 8:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma

Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023

Aug 4, 2023, 8:30 AM EDT - 1 year ago

Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023

Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%

Jul 13, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%

Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

Jul 12, 2023, 8:00 AM EDT - 1 year ago

Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

Biofrontera Inc. Announces 1-for-20 Reverse Stock Split

Jul 3, 2023, 9:15 AM EDT - 1 year ago

Biofrontera Inc. Announces 1-for-20 Reverse Stock Split

Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.

Jun 12, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.

Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT

Jun 1, 2023, 9:15 AM EDT - 1 year ago

Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT

Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer

May 30, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer

Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects

May 15, 2023, 9:50 AM EDT - 1 year ago

Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects